LNA Santé SA (LNA.PA) - Deep Dive Research Report

Prepared 2026-06-15. Listing: Euronext Paris, ticker LNA, ISIN FR0004170017. Sector: Healthcare (medico-social and care facility operator).

A note on "concalls": LNA Santé is a French small/mid-cap that does not produce English-language earnings-call transcripts. It reports operating revenue quarterly and full results half-yearly, presenting each at an SFAF (Société Française des Analystes Financiers) analyst meeting accompanied by a detailed press release and slide deck. This report treats the five most recent reporting events as the "concall" equivalent and cites them as such:

1. Q1 2026 revenue - published mid-April 2026 (within 90 days of today ✓)
2. FY2025 annual results - board meeting 24 March 2026, SFAF meeting same week
3. 9M / Q3 2025 revenue - published ~22 October 2025
4. H1 2025 results - published 25 July 2025, SFAF meeting
5. Q1 2025 revenue - published ~April 2025

SECTION 1: WHAT THE COMPANY DOES

LNA Santé runs places where frail and sick people are cared for. Concretely, it owns and operates a network of physical establishments across France (plus a handful in Belgium and Poland): medicalised retirement homes for dependent elderly people, rehabilitation clinics where patients recover after surgery or illness, psychiatric clinics, a few surgical clinics, and a fast-growing home-hospitalisation business that sends medical teams to treat acute patients in their own homes. It employs roughly 9,000 people and looks after on the order of 9,000-plus patients and residents at any given time, across about 87 establishments holding around 10,100 beds/places.

The company was founded in Nantes in 1990 under the name Le Noble Âge, and it remains family-controlled to this day by the founding Siret family. Two decisions in its early history shaped what it is now. In 1995 it opened a facility dedicated to Alzheimer's care, committing early to specialised, higher-acuity elderly care rather than generic accommodation. In 1999 it moved into medical rehabilitation (SSR, now relabelled SMR - "soins médicaux et de réadaptation"), planting the seed of what is today a genuinely diversified care group rather than a pure nursing-home operator. In 2016 it rebranded from Le Noble Âge to LNA Santé, signalling the shift from "old-age homes" to "health". In 2023 it adopted entreprise à mission status (a French legal form binding the company to stated social and environmental purposes) under a 2023-2028 strategic plan called "Grandir Ensemble" ("Growing Together").

The core value proposition is twofold. To the public health system, LNA Santé provides regulated capacity in segments where French demand structurally exceeds a state-frozen supply: dependency beds, rehabilitation places, and home hospitalisation. To residents and patients and their families, it sells quality of care and a reputation for clean management at a time when the entire French private-care sector is recovering from a reputational catastrophe (the 2022 Orpea "Les Fossoyeurs" scandal that exposed neglect and financial abuse across the largest commercial operator). LNA Santé's ~93% occupancy rate, materially above its scandal-hit large peers, is the clearest market evidence that this proposition is working.

What makes the business genuinely hard to replicate is not the buildings - it is the authorisations. Every elderly-care bed, rehabilitation place and home-hospitalisation zone in France requires an administrative licence from the regional health authority (the ARS). New capacity creation is effectively frozen. That turns the existing licensed footprint into a scarce, defensible asset, and it makes acquisition of existing operators - not greenfield construction - the only realistic path to growth at scale.

A concrete example of the business in action: a 78-year-old has a hip replacement in a public hospital. The hospital wants the bed back within days. The patient is transferred to an LNA Santé SMR rehabilitation clinic for several weeks of physiotherapy, paid for largely by the public health insurance system on a regulated tariff. If she could recover at home instead, LNA Santé's HAD (hospitalisation à domicile) arm can send nurses and equipment to her flat, again reimbursed by the state. If she later becomes permanently dependent, she may move into one of the group's EHPAD nursing homes, where she pays an accommodation fee out of pocket (or via social aid) on top of state-funded care. The group can capture a patient across an entire late-life care pathway.

Management frames the strategy around the Grandir Ensemble mission: "soigner et prendre soin des personnes fragilisées" - to treat and to care for vulnerable people - with residents and patients positioned as "the number one priority." (LNA Santé corporate site, Discover LNA Santé)

SECTION 2: BUSINESS SEGMENTS

LNA Santé reports along two financial axes. The dominant one is Exploitation (the operating business - running care establishments), which is roughly 96% of revenue. The second is Immobilier (real estate development), roughly 4%. Within Exploitation the company increasingly splits its disclosure into Soin (Healthcare: rehabilitation, home hospitalisation, psychiatry, surgery) and Hébergement (Accommodation: the EHPAD nursing homes). The structure below follows the way the business actually operates.

2.1 Hébergement - EHPAD nursing homes (the historical core)

This is what the company was built on: medicalised retirement homes (EHPAD) for dependent elderly people. As of 2025 the group runs roughly 47 EHPADs in France with around 4,795 beds, plus 4 nursing homes in Belgium (~538 beds). EHPAD is now around 38% of operating revenue and growing slowly (+3.0% organic in Q1 2026, +2.2% in H1 2025) - this is the cash-generative, mature base rather than the growth engine.

The core capability here is occupancy and care quality at scale under tight regulation. EHPAD revenue has three tariff layers: a "soins" (care) envelope funded by health insurance, a "dépendance" envelope co-funded by the local département, and an "hébergement" (accommodation) fee paid by the resident. Running these profitably while keeping occupancy near full and quality high is operationally demanding, and the post-Orpea environment has made reputation a hard commercial moat. LNA Santé's ~93% occupancy versus 86.5% at emeis and ~90% at Clariane is the segment's scoreboard.

It exists as a distinct activity because its economics (out-of-pocket accommodation fees, long average stays, dependency-driven demand) and its regulator interactions differ from acute medical care. Strategically, management treats it as the cash cow and the reputational anchor, not the place where incremental capital is deployed fastest.

2.2 Soin - Healthcare: SMR rehabilitation, HAD home hospitalisation, psychiatry, surgery (the growth engine)

This is where LNA Santé differs most sharply from a plain nursing-home operator, and where almost all growth now comes from. It bundles:

• SMR / SSR rehabilitation clinics - around 18 establishments, ~2,949 places. Patients recover here after surgery, stroke, or serious illness.
• HAD - hospitalisation à domicile (home hospitalisation) - around 11 structures, ~1,210 places. This is the fastest-growing line in the entire group: patients pris en charge (patients treated) rose +23.1% year-on-year in Q1 2026, and HAD has climbed from roughly 12% to 16% of operating revenue in recent years.
• Psychiatric clinics - around 2, ~339 beds.
• Surgical establishments - around 4, ~159 beds.
• Rehabilitation in Poland - around 2, ~125 places (the Polish operation grew +34.3% in H1 2025 off a small base).

The core capability is operating acute and sub-acute medical facilities - a different regulatory and clinical animal from accommodation. It requires medical staffing, clinical governance, and integration with the public hospital system that refers patients. HAD in particular is a structurally favoured model: the French state wants to shift care out of expensive hospital beds and into the home, and the HAD market in France is projected to exceed €4 billion by 2030 (Ehpad Invest). LNA Santé "anticipated the market mutation" by investing early.

Competitive position: in SMR and HAD the competitor set is broader and less concentrated than in EHPAD - it includes regional non-profits, public hospitals, and specialised operators rather than just the big four nursing-home groups. LNA Santé wins on having moved early and on operating these as part of an integrated pathway. Management talks about Soin as the priority growth area and the source of its diversification advantage and "modern image less associated with scandals."

2.3 Immobilier - Real estate development (the value-arbitrage option)

LNA Santé develops the real estate its operations sit in, and periodically sells finished assets to long-term real estate investors under secured commercial leases (a develop-and-externalise model). This segment is roughly 4% of revenue but lumpy and high-margin: in FY2025 total real estate disposals reached €47.8 million, 3.8x the 2024 level, materially boosting reported group results. In Q1 2026, by contrast, real estate revenue fell to €6.4m (from €10.3m) simply because no major disposal landed in the quarter.

The capability is in-house property development plus the relationships with institutional real estate buyers who want long-leased healthcare assets with a creditworthy operator-tenant. It exists separately because its economics (project-based, capital-intensive, deal-timing-driven) are nothing like recurring care revenue. Strategically it is the option/lever: it funds the operating business's expansion, manages the group's own-versus-leased property mix, and crystallises property value when timing is favourable. It is the main reason group reported results can swing year to year even when operations grow steadily.

Segment summary

SECTION 3: PRODUCTS AND BUSINESS DETAIL

The "products" are licensed care establishments. As of 2025 the operating footprint is roughly 87 establishments / ~10,115 beds and places, broken down as:

• EHPAD medicalised retirement homes - ~47 in France, ~4,795 beds
• SMR medical-care and rehabilitation clinics - ~18, ~2,949 places
• HAD home-hospitalisation structures - ~11, ~1,210 places
• Belgian nursing/care homes (MRS) - ~4, ~538 beds
• Psychiatric clinics - ~2, ~339 beds
• Surgical establishments - ~4, ~159 beds
• Polish rehabilitation establishments - ~2, ~125 places

Operating revenue (Exploitation) was about €793.9m in FY2024, grew +10.6% reported in FY2025 (to roughly €865-880m, including a Ségur social-funding reclassification effect that flatters the reported figure relative to the ~9% underlying), and is guided to about €925m in FY2026 (excluding acquisitions). Beyond operations there is the Immobilier development activity (~€48m of disposals in FY2025).

What makes the "product" hard to replicate is regulatory rather than industrial. Each bed type requires its own ARS authorisation; new authorisations are essentially frozen; clinical staffing must meet regulated ratios; and post-Orpea, inspection intensity is high. Process knowledge - running an EHPAD at near-full occupancy, staffing an SMR clinic, coordinating an HAD network across a geography, and navigating three-layer tariff funding - is accumulated operating capital. The barrier to a new entrant is not building a building; it is obtaining the licences, the medical staff, and the reputation simultaneously.

Geographically the group is overwhelmingly French, with a small Belgian nursing-home presence (long-standing, slower-growing, +5.5% H1 2025) and an early-stage Polish rehabilitation foothold (small base, +34.3% H1 2025). The internationalisation is deliberate but secondary; France is the core and the regulatory home market.

Notable milestones: 1990 founding (Nantes); 1995 first dedicated Alzheimer's unit; 1999 entry into rehabilitation; 2016 rebrand to LNA Santé; 2023 entreprise à mission status and the Grandir Ensemble plan; and the ongoing build-out of HAD that has taken it from ~12% to ~16% of operating revenue.

SECTION 4: CUSTOMERS

LNA Santé has, in effect, two customers for every patient: the patient/family who chooses the facility, and the French state that funds most of the care.

Who buys. For EHPAD, the decision-makers are the dependent elderly person's adult children, often under time pressure following a hospital discharge or a fall. Their criteria are location (proximity to family), reputation/safety (acutely sensitive post-Orpea), quality of care, and the out-of-pocket accommodation fee. The sales cycle can be days when triggered by a medical event. For SMR and HAD, the "customer" who routes the patient is the public hospital discharging them; the referring physician and hospital discharge coordinator choose where a recovering patient goes, on criteria of clinical capability, available capacity, and geographic fit. For all care lines, the dominant payer is the state (health insurance for the soins envelope, départements for dependency), which sets tariffs - so pricing is largely administered, not negotiated.

Why they choose LNA Santé. Reputation and occupancy are the visible signals: a ~93% occupancy rate in a sector where the largest players sit in the mid-80s to ~90% tells you families and hospital referrers are actively selecting LNA Santé. Its relative absence from the scandal headlines that engulfed Orpea/emeis is a live commercial advantage. For hospital referrers, its integrated SMR + HAD offering means it can take a wider range of post-acute cases.

Switching costs. At the individual level, switching an elderly resident between EHPADs is emotionally and physically disruptive, so once placed, residents tend to stay (long average length of stay underpins revenue stability). At the system level, the binding lock-in is the ARS authorisation: a competitor cannot simply open across the road because new licences are not granted. For SMR/HAD, the embedded relationships with referring hospitals create a softer but real switching cost.

Concentration. There is no single dominant private customer - revenue is diffused across thousands of residents and patients. The genuine concentration is payer concentration: the French state and its tariff decisions drive a large share of revenue. That makes regulation, not customer churn, the dominant revenue-predictability factor.

Contract structure. EHPAD accommodation is paid by residents (or social aid) on rolling terms; care funding flows on regulated annual tariff envelopes; SMR/HAD revenue is reimbursement-based per episode of care. The result is highly recurring, demand-backed revenue with a high degree of administrative predictability - punctuated by the lumpier, deal-driven Immobilier line.

SECTION 5: COMPETITIVE LANDSCAPE

The French commercial elderly-care market is concentrated at the top and fragmented below. The five largest commercial groups run roughly 13% of all EHPADs and 14% of beds nationally; the rest is a long tail of non-profit and public operators. LNA Santé sits as a mid-sized, high-quality operator - commonly ranked 4th-7th by EHPAD beds - that is "around seven times smaller than emeis or Clariane" but grows faster and runs cleaner.

The named competitors:

• Clariane (ex-Korian) - France, listed Euronext Paris (CLARI). The market leader by EHPAD beds (~23,000 beds in ~269 EHPADs). Diversified across Europe; has spent recent years deleveraging and selling assets.
• emeis (ex-Orpea) - France, listed Euronext Paris (EMEIS). ~20,000 EHPAD beds. The epicentre of the 2022 "Les Fossoyeurs" scandal; completed a massive ~€3.15bn refinancing in late 2025 and a near-total equity restructuring/dilution. Recovering occupancy (~86.5%) but reputationally scarred.
• DomusVi - France, Private. ~22,000 EHPAD beds, the second-largest by capacity.
• Colisée - France, Private (PE-backed). Went through a restructuring phase in early 2025.
• Domidep, Emera, Vivalto, SEDNA, Iroise Bellevie - France, Private. The mid-tier peer set; Domidep in particular is, like LNA Santé, prized on the secondary market for management quality.

(Market caps are approximate peer-size references only, as of June 2026, and move with the market; emeis's figure in particular is distorted by its post-restructuring share count.)

Why LNA Santé wins or loses. It wins on growth (+6.5% organic Q1 2026 vs emeis ~+6%, Clariane ~+4.8%), on occupancy (~93%), on a clean reputation, and on a more diversified, more "medical" mix (HAD/SMR) that is both higher-growth and less scandal-exposed than pure EHPAD. It loses on scale: it cannot match the national density, purchasing power, or balance-sheet firepower of Clariane/emeis/DomusVi, which constrains how fast it can consolidate.

Barriers to entry are high and structural: ARS authorisations are frozen, so capacity is scarce and growth happens by acquiring existing operators; clinical staffing and reputation take years to build; and the post-Orpea regulatory scrutiny raises the cost of operating poorly. This is not a commoditised business, but it is a regulated, capital-intensive one where margins are administered rather than expanded freely - so the moat is real (scarce licences, reputation) but the ceiling on profitability is set by the state.

Structural shifts: consolidation continues (the big groups have spent recent years restructuring and selling rather than expanding), which opens acquisition opportunities for a disciplined, well-capitalised mid-cap like LNA Santé. The demand-side tailwind (ageing) is colliding with frozen supply, tightening the value of existing licensed beds.

SECTION 6: INDUSTRY

Demand drivers. The single dominant driver is French demographics. There are roughly 670,000 severely dependent seniors in France in 2025, and the population aged 85+ is set to rise sharply through 2040. About 570,000 people live in EHPADs across roughly 7,300 establishments of all ownership types. Demand for medicalised dependency beds, post-acute rehabilitation, and home hospitalisation is structurally rising as the population ages.

Supply is frozen. Critically, between 2019 and 2023 the number of EHPAD beds actually fell slightly, even as demand rose, because new bed creation is gated by the regional health authorities (ARS). Demand for medicalised beds is structurally above supply, and that gap is widening. This is the defining feature of the industry: a regulated supply ceiling sitting under a demographic demand surge.

Market size and structure. The commercial EHPAD market is led by Clariane, DomusVi and emeis, with five groups controlling ~13% of establishments and ~14% of beds; the majority remains public and non-profit. The HAD home-hospitalisation market is a separate, faster-growing pool projected to exceed €4bn in France by 2030, supported by state policy that wants care shifted out of hospitals and into homes.

Regulation. This is a heavily administered sector. Tariffs are set across three funding streams (health insurance, départements, residents). The "Ségur" agreements raised and reclassified social-care funding, which has flowed through operator revenue (and complicates year-on-year comparisons - LNA Santé reports both reported and Ségur-neutralised organic growth). The LFSS (social security financing law) for 2024, amended by LFSS 2025, launched an experiment to simplify EHPAD tariff-setting and lets public/non-profit EHPADs raise fees for non-subsidised residents. For 2026, tariffs were set to rise only slightly. The net effect: revenue is supported by demographics but capped by the state's willingness to fund and to authorise capacity.

Cyclicality. Operating demand is close to non-cyclical - dependency and post-acute care needs do not track the economy. The cyclical exposures are financial (interest rates on the sector's heavy property debt) and political (tariff decisions, regulatory crackdowns). The Immobilier development line is genuinely cyclical, sensitive to real estate investor appetite and rates.

Tailwinds: ageing demographics, frozen supply raising the value of existing licences, policy support for HAD, and sector consolidation creating acquisition targets. Headwinds: administered tariffs that cap pricing power, staffing shortages and wage inflation in care, heightened regulatory/inspection intensity post-Orpea, and interest-rate sensitivity of a property-heavy sector.

SECTION 7: GROWTH TRIGGERS

All triggers below are drawn from the five most recent reporting events.

• FY2026 operating revenue target of ~€925m (ex-acquisitions), ~+5% organic, with preserved operating margins. Confirmed at Q1 2026 (Q1 2026 revenue release, ~April 2026). Repeated/affirmed at the FY2025 results (24 March 2026).

• HAD home-hospitalisation is the primary growth engine, with patients treated +23.1% YoY. (Q1 2026 revenue release, ~April 2026). HAD has been the recurring growth theme across all five periods, rising from ~12% to ~16% of operating revenue.

Q1 2026 growth was driven 84% by healthcare services, with HAD patients pris en charge up 23.1% year-on-year (Q1 2026 revenue release).

• "Grandir Ensemble" plan targeting ~€1bn revenue and ~12,000 beds. Reaffirmed through 2025 (H1 2025 results, 25 July 2025). Repeated across periods as the medium-term framework.

• External growth (acquisitions) funded by balance-sheet capacity. Management has stated it has "the means to dedicate an investment plan to external growth" (interview tied to FY2024 results, Deputy CEO Damien Billard) and reiterated the targeted-acquisition strategy at FY2025 (24 March 2026). With net debt down and leverage at 1.4x, this is an explicitly available lever.

• Real estate disposals as a value lever - €47.8m of disposals in FY2025 (3.8x 2024), with the development pipeline a recurring source of value crystallisation (FY2025 results, 24 March 2026). Note: timing-dependent; Q1 2026 had no major disposal.

• International ramp in Poland (rehabilitation) off a small base, +34.3% in H1 2025, and steady Belgian growth (+5.5%). (H1 2025 results, 25 July 2025).

• Progressive in-year guidance upgrades - the FY2025 operating-revenue target was raised from €845m to €860m at H1 2025 (H1 2025 results, 25 July 2025) and confirmed at 9M (Q3 2025 release, ~Oct 2025), evidencing momentum carried into the €925m FY2026 target.

SECTION 8: KEY RISKS

Tariff and regulatory risk (high probability, moderate-to-high impact). Because the French state sets care tariffs across three funding envelopes, LNA Santé's pricing power is structurally capped. A stingy tariff cycle, an unfavourable reform of the EHPAD tariff experiment, or a clawback of Ségur funding would compress margins directly. Management already flags this: H1 2025 operating margin held at 7.8% "despite unfavourable tariff changes," which is an explicit acknowledgement that tariff moves are a live drag and that the company is currently absorbing rather than passing them through.

Reputational/regulatory crackdown risk (low probability, catastrophic impact). The Orpea scandal showed that one exposé of neglect or financial abuse can destroy a private-care operator's equity and trigger sector-wide regulatory tightening. LNA Santé's ~93% occupancy and clean reputation are its biggest asset and its biggest single point of failure: a serious care-quality or governance scandal would hit occupancy (the whole model), funding, and acquisition ambitions simultaneously. The mechanism is reputational contagion in a sector the public already distrusts.

Staffing shortages and wage inflation (high probability, moderate impact). French care faces chronic shortages of nurses and care staff. Rising wages in a tariff-capped revenue model squeeze margins from both ends. Because labour is the dominant cost in care, even modest wage inflation that outpaces tariff increases directly erodes profitability.

Interest-rate and real estate risk (moderate probability, moderate impact). The sector is property-heavy and the Immobilier line depends on institutional buyers' appetite for long-leased healthcare assets. Higher-for-longer rates raise financing costs, reduce disposal valuations, and could make the lumpy real estate gains - which materially flattered FY2025 results (€47.8m of disposals) - harder to repeat. A year with no major disposal (as in Q1 2026) shows how quickly that contribution can disappear.

Acquisition execution risk (moderate probability, moderate impact). Growth to the €1bn / 12,000-bed target relies substantially on buying existing operators in a consolidating market. Overpaying, integrating poorly, or inheriting quality/compliance problems from an acquired operator are real risks, especially when competitors are also hunting and when the cleanest assets command premiums.

Founder/family concentration and succession (low probability, structural). The Siret family controls the company. This aligns interests (and the recent insider buying is a positive signal of that alignment), but it concentrates key-person and succession risk, and minority shareholders have limited ability to force change.

SECTION 9: WALK THE TALK

The five reporting events used: Q1 2025 revenue (~April 2025); H1 2025 results (25 July 2025); 9M/Q3 2025 revenue (~22 October 2025); FY2025 results (24 March 2026); Q1 2026 revenue (~April 2026). The most recent is within ~60 days of today. (Underlying FY2024 guidance, set in early 2025, provides the baseline against which 2025 delivery is judged.)

The clearest test of this management team is its guidance discipline through 2025, and the pattern is one of conservative targets steadily beaten and then raised. Coming out of FY2024 (operating revenue €793.9m, +10.3% reported), management framed 2025 around continued mid-single-digit organic growth. At H1 2025 they reported +7.5% organic growth, an operating margin held at 7.8% despite adverse tariff moves, and they raised the full-year operating-revenue target from €845m to €860m.

At H1 2025 (25 July 2025) the company explicitly lifted its annual operating-revenue objective to €860m "thanks to these good results and encouraging prospects."

That raised €860m target was then confirmed, not quietly walked back, at the 9M update (~October 2025), where nine-month operating revenue was up +11.4% reported (+9.1% Ségur-neutralised) and Q3 alone up +11.2%. By FY2025 (24 March 2026), management delivered: reported operating revenue +10.6%, net income (group share) €24.1m (+10.7%), operating net income €28.1m at a 3.2% margin, and a deleveraging to net debt of €107.3m and 1.4x leverage (from €111.7m / 1.5x). They also delivered a large step-up in real estate disposals (€47.8m, 3.8x 2024), which they had flagged as a lever. So the FY2025 outcome matched or exceeded the in-year guidance trail.

Carrying into 2026, the Q1 2026 update showed +6.5% organic growth, ahead of the ~+5% full-year target set just weeks earlier, with the €925m FY2026 revenue target confirmed and margins guided to be preserved. The recurring HAD growth story they have told across every period (the shift from ~12% to ~16% of revenue) is visibly being executed, with Q1 2026 HAD patients +23.1%.

On capital returns, management has also done what it said: the dividend has risen every year (€0.50 → €0.60 → €0.65, with FY2025 proposed materially higher), consistent with their stated intent to share growth with shareholders while deleveraging.

The one area where reported figures flatter the underlying business is the real estate and Ségur-reclassification effects, which management is transparent about (they publish Ségur-neutralised organic growth alongside reported figures), but a careful reader should separate the lumpy property gains from the recurring care growth.

Assessment: this is management that does what it says, and slightly under-promises. Guidance has been conservative, raised mid-year, and met. The credibility caveat is not honesty but composition: a meaningful slice of reported FY2025 profit growth came from lumpy real estate disposals, so the recurring operating trajectory is a touch less spectacular than the headline. Net, a credible, consistent, founder-aligned team.

SECTION 10: SHAREHOLDER FRIENDLINESS INDEX

Dividends. LNA Santé has paid and grown its dividend every year for the better part of a decade. Over the last three completed fiscal years the trend is steadily up: €0.60 per share for FY2023 (paid July 2024), €0.65 for FY2024 (paid July 2025), and a proposed FY2025 dividend of around €0.85 per share per the 24 March 2026 results communiqué (one company source tied to the Q1 2026 release cited €0.95; the final figure is set at the June 2026 AGM, and the discrepancy is unresolved in public sources). Either way it is a clear, sizeable increase on the €0.65 prior year, consistent with the FY2025 earnings growth (+10.7%) and the deleveraging. The payout is comfortably covered by earnings, so the rising dividend reflects confidence rather than balance-sheet strain.

Buybacks and dilution. LNA Santé maintains a standing share-buyback authorisation (renewed at the 18 June 2025 AGM; the prior 19 June 2024 authorisation permitted up to 10% of capital, i.e. ~1,070,941 shares, at up to €80/share). In practice the programme is used mainly for liquidity provision (~34,416 shares), employee/management share plans (~147,250 shares), and as acquisition currency, with a portion (~302,052 shares) earmarked for possible cancellation. The company held roughly 483,718 treasury shares, ~4.52% of capital (against ~10.7m shares outstanding). MoatMap recorded zero open-market buybacks in the trailing ~90 days (since 17 March 2026), and no large cancellation-driven buyback programme is evident over the last three years - this is a liquidity-and-plans buyback, not a capital-return buyback. Share count has been broadly stable, with only modest dilution from employee plans offset by the treasury holding; this is not a company aggressively retiring stock, nor one diluting shareholders meaningfully.

Verdict: Returns Capital (moderate) - a consistently growing, well-covered dividend is the primary return, while the buyback serves liquidity/M&A rather than shrinking the share count.

SECTION 11: INSIDER ACTIVITIES

Listing venue: Euronext Paris, so insider transactions are AMF "déclarations des dirigeants" (MAR Article 19 PDMR notifications). The MoatMap block (market EU) is the spine; I cross-checked the most recent weeks against the AMF/abcbourse aggregation of those filings and found additional, larger buys not in the MoatMap block, which materially change the read. The MoatMap block is not marked stale but covers only 2 of the recent transactions.

Recent transactions (most recent first):

(Source: AMF directors' dealings, as aggregated; e.g. AMF declaration, 2026-04-10 for the block purchase. The two most recent rows match the injected MoatMap EU block.)

Buys - read the signal. The standout is the Chairman and founder, Jean-Paul Siret, buying through Financière Vertavienne 44 - including a single open-market block of 132,373 shares for roughly €3.49 million on 10 April 2026, followed by a steady drumbeat of additional smaller open-market purchases through April, May and into June 2026. This is a very bullish signal. A founder-chairman deploying ~€3.5m of his own capital in a single open-market purchase, then continuing to add over the following two months, is the strongest form of insider conviction: it is concentrated, it is by the most informed person in the company, and it is sustained rather than a one-off. It also lines up in time with the FY2025 results (24 March 2026) and the upgraded FY2026 guidance, suggesting the founder views the post-results price as attractive relative to his own view of the business.

Sells - work out the why. Insider selling here is minor and mostly mechanical. The 22 September 2025 "sale" of 3,450 shares by CEO Willy Siret was matched same-day, same-size, same-price by a buy from another family holding (Immobilière du Vallon, Jean-Paul Siret) - this is an intra-family transfer between holding vehicles, not a true reduction in family ownership, and carries no negative signal. The only genuine open-market sale is the small 2,000-share (~€49k) sale by Willy Siret on 26 August 2024; reason not disclosed, but at that size it is consistent with routine personal liquidity rather than a view on the business.

Net assessment. Insiders are decisively net buyers, and the activity is concentrated in the founding family - above all the Chairman. The ~€3.5m April 2026 block plus the sustained follow-on buying is a textbook conviction signal, reinforced by an outside institutional investor (BNP Paribas Développement) also accumulating. The only selling is an intra-family reshuffle plus one small personal sale. Read: bullish insider signal, anchored by a large, sustained, open-market founder purchase.

SECTION 12: SCENARIOS

Bull case. Demographics do what demographics do: the 85+ population keeps rising while the ARS keeps the bed taps closed, so every licensed bed LNA Santé owns becomes more valuable and occupancy stays pinned near 93%. The HAD home-hospitalisation business keeps compounding at the 20%-plus patient-growth rates seen in early 2026, riding the state's deliberate push to move care out of hospitals, and it grows from ~16% toward a much larger slice of revenue - dragging the group mix toward higher-growth, higher-reputation "medical" services and away from scandal-tainted plain nursing homes. The founder's heavy April 2026 buying proves prescient: management hits the €925m FY2026 target, keeps deleveraging, and uses its clean balance sheet to acquire well-run mid-tier operators cheaply while the big groups are still licking their wounds, marching toward the €1bn / 12,000-bed goal. The clean-reputation premium widens as competitors stumble, and well-timed real estate disposals keep crystallising value on top. LNA Santé ends up the quality consolidator of a structurally short market.

Base case. Management does roughly what it has guided. Operating revenue grows mid-single-digit organically with HAD as the engine, EHPAD ticks along in the low single digits, and the group lands near its €925m FY2026 target with margins held. Tariff cycles stay grindingly tight, so margins do not expand but do not collapse; wage inflation is absorbed. Real estate disposals contribute lumpily, flattering some years and absent in others, so reported results stay choppier than the smooth operating trend. The dividend keeps rising modestly, the family keeps control, and a couple of bolt-on acquisitions nudge the footprint up. It remains a well-run, faster-than-peers, mid-sized operator in a regulated, slow-but-certain demand environment - solid, unspectacular, demographically underwritten.

Bear case. The bind is regulatory and reputational. A harsh tariff reform, or a Ségur-funding clawback, squeezes the administered care envelopes just as care-staff wages keep climbing, and the 7.8% operating margin starts eroding because LNA Santé cannot raise prices to compensate. Worse, the company is not immune to the sector's reputational fragility: a serious care-quality or governance failure at even one establishment - in a public already primed to distrust private elderly care after Orpea - hits occupancy across the network, the one variable the whole model depends on, and freezes its acquisition ambitions. Higher-for-longer rates simultaneously raise financing costs on a property-heavy balance sheet and dry up the institutional appetite for the real estate disposals that have been padding reported profit, so a couple of years pass with no major disposal and visibly weaker headline results. Acquisitions, the path to the €1bn target, get harder and pricier as everyone chases the same scarce clean assets. Growth slows to a regulated crawl, and the quality premium that justified the franchise narrows.

Further reading (Section 13) is omitted: SemiAnalysis, Stratechery, and MBI Deep Dives focus on technology, semiconductors, and global equity deep dives respectively, and none has published coverage of LNA Santé.

Sources

• Ehpad Invest - LNA Santé Q1 2026
• Webdisclosure - LNA Santé Q1 2026 results
• Investing.com - LNA Santé bénéfice net 2025 +10,7%
• Zonebourse - LNA Santé solide sur l'exercice 2025
• LNA Santé corporate site - Discover LNA Santé
• Cap Retraite - Top groupes EHPAD France
• Revente EHPAD - Classement des groupes EHPAD 2026
• Ehpad Invest - LNA Santé, le petit géant
• Webdisclosure - LNA Santé CA 3ème trimestre 2025
• Zonebourse - LNA Santé +11% CA exploitation 9 mois
• abcbourse - LNA Santé résultats semestriels et objectif relevé
• LNA Santé - Résultats annuels 2024 (CP)
• LNA Santé - Programme de rachat d'actions juin 2025
• tradingsat / BFM Bourse - Dividende LNA Santé
• abcbourse - LNA Santé transactions des dirigeants (AMF)
• CNSA - Réforme de la tarification des EHPAD
• Revente EHPAD - Marché des EHPAD en France
• Boursorama - Cours Clariane (market cap reference)

Two reconciliation notes for the user: (1) the FY2025 dividend is reported as ~€0.85 in the 24 March 2026 results communiqué but as €0.95 in the Q1 2026 release - I flagged this and used €0.85 in the chart; the final figure is the June 2026 AGM's. (2) The insider data is materially richer than the injected MoatMap block - AMF filings show a ~€3.49m founder block buy on 2026-04-10 plus sustained follow-on buying that the 2-row MoatMap block omitted, which I treated as the dominant Section 11 signal.